Abstract
Tyrosine kinase inhibitors still play a very important role in the treatment of metastatic renal cell carcinoma despite a continuously changing scenario, in which immunotherapy and several combination-based approaches are also available. In this light, patient-reported outcomes and health-related quality of life are important factors in the selection of the best first-line treatment. This Review focuses on the existing evidence on patient-reported outcomes and health-related quality of life with several tyrosine kinase inhibitors (pazopanib, sunitinib, cabozantinib and tivozanib) used as first-line treatment for metastatic renal cell carcinoma.
Original language | English |
---|---|
Pages (from-to) | 2657-2666 |
Number of pages | 10 |
Journal | Future Oncology |
Volume | 15 |
Issue number | 22 |
DOIs | |
Publication status | Published - Aug 1 2019 |
Keywords
- mRCC
- patient-reported outcomes
- quality of life
- TKIs
ASJC Scopus subject areas
- Oncology
- Cancer Research